二甲氨基菊酯的药理学作用研究进展  

Research progress on pharmacological action of DMAMCL

作　　者：马婧 赵作伟[2] 李曼[1] MA Jing;ZHAO Zuowei;LI Man(Department of Oncology, the Second Affiliated Hospital of Dalian Medical University, Dalian 116027,China;Department of Breast Surgery, the Second Affiliated Hospital of Dalian Medical University, Dalian 116027, China)

机构地区：[1]大连医科大学附属第二医院肿瘤科,辽宁大连116027 [2]大连医科大学附属第二医院乳腺外科,辽宁大连116027

出　　处：《大连医科大学学报》2021年第1期64-69,共6页Journal of Dalian Medical University

基　　金：国家自然科学基金项目(81872156,81673762)。

摘　　要：二甲氨基菊酯(DMAMCL,即ACT001)是一种通过含笑内酯(michelioide,MCL)的二甲氨基Michael加成反应合成的化疗药物,具有较好的缓释作用和较高的口服生物利用度。研究表明,DMAMCL具有抗肿瘤、神经保护与抗炎等多种生物药理学活性,具有重要的临床应用价值。本文综述了DMAMCL的药理学作用,为其进一步开发利用提供科学依据。Dimethylaminomicheliolide(DMAMCL,i.e.,ACT001)is a chemotherapeutic drug synthesized by dimethylamino Michael addition reaction of micheliolide(MCL),and it has good sustained release effect and high oral bioavailability.Studies have shown that DMAMCL has a variety of bio-pharmacological activities,including anti-tumor,neuroprotection and anti-inflammation.Therefore,DMAMCL has great clinical application value.This paper reviews the pharmacological action of DMAMCL,aiming to provide scientific basis for its further development and utilization.

关 键 词：二甲氨基菊酯 药理作用 研究进展 

分 类 号：R96[医药卫生—药理学]